Note 2 - Equity Method Investment

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Equity Method Investments and Joint Ventures Disclosure [Text Block]

NOTE

2

– EQUITY METHOD INVESTMENT

The Company has an equity method investment in Helomics. The unaudited

nine

-month condensed statement of operations is as follows:

Helomics Holdings Corporation
	For the Nine Months Ended
	September 30, 2018
Revenue	$	623,662
Gross margin	$	441,370
Net loss from continuing operations	$	(6,833,846	)
Net loss to investee	$	(5,227,552	) 1

1

The loss to investee was calculated at

80%

for the initial period of ownership,

January 11, 2018 –

February 27, 2018,

and then at

75%

for the remainder of the

nine

-month period at the current equity investment percentage owned by the Company.

Helomics’

first

nine

months predominantly included diagnostic revenue only. The contract research organization and D-CHIP Artificial Intelligence products are in the process of launching and have generated approximately

$31,000

of revenue in the

third

quarter.